Drug, across the briefings
Durvalumab across 19 cancers
Durvalumab appears in 19 of the briefings; its FDA label names 9 of those diseases.
| Disease | FDA label | Open Targets stage, on which gene | Trials | Active |
|---|---|---|---|---|
| Bladder cancer | label names disease | phase 4 on CD274 | 48 | 23 |
| Cholangiocarcinoma | label names disease | phase 4 on CD274 | 44 | 33 |
| Endometrial cancer | label names disease | — | — | |
| Esophageal cancer | label names disease | phase 4 on CD274 | 29 | 16 |
| Gallbladder cancer | label names disease | — | — | |
| Gastric cancer | label names disease | phase 4 on CD274 | 23 | 12 |
| Hepatocellular carcinoma | label names disease | — | — | |
| Lung cancer | label names disease | phase 4 on CD274 | 167 | 68 |
| Small cell lung cancer | label names disease | phase 4 on CD274 | 66 | 35 |
| Anal cancer | phase 4 on CD274 | 2 | 1 | |
| Cervical cancer | phase 4 on CD274 | 18 | 5 | |
| Cutaneous squamous cell carcinoma | phase 4 on CD274 | — | — | |
| Head and neck cancer | phase 4 on CD274 | 51 | 8 | |
| Hodgkin lymphoma | phase 4 on CD274 | 3 | 0 | |
| Kidney cancer | phase 4 on CD274 | 18 | 6 | |
| Merkel cell carcinoma | phase 4 on CD274 | 7 | 1 | |
| Mesothelioma | phase 4 on CD274 | 12 | 2 | |
| Nasopharyngeal carcinoma | phase 4 on CD274 | 2 | 0 | |
| Vulvar cancer | phase 4 on CD274 | 3 | 0 |
The label column is the briefing's openFDA stage: a label whose Indications and Usage names the disease. The Open Targets column is the furthest clinical stage recorded for the drug against any gene on that briefing's target list, in any indication. Trials are ClinicalTrials.gov interventional studies naming the drug and the disease, from the briefing's trials stage; a dash means the briefing did not search this drug in that disease (it searches the drugs Open Targets lists against its own genes), which is not the same as none. Salt forms, biosimilar suffixes and formulation words are merged by the same rule the briefings use.